Thursday, March 09, 2006
Administration Oversight
Documents obtained by Rep. Waxman undercut FDA’s claim that the Plan B application raised “novel” issues requiring extended additional analysis.
Administration Oversight
New Documents Show FDA Mischaracterized Its Review of PlanB
Documents and Links
Rep. Waxman's Letter to FDA (275 KB)
